AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sotera Health Co (NASDAQ:SHC)
15.27 USD
+0.250 1.664%Sponsored Reports
Loading...
| Previous Close (in USD) | 15.02 |
|---|---|
| Change | +0.250 1.664% |
| 52 W H/L (in USD) | 19.400/10.710 |
| EBITDA (in USD) | 527.352M |
| PE Ratio | 58.95 |
| Volume | 2480845 |
| Diluted Eps TTM | 0.19 |
| Total Assets (in USD) | 3130.42M |
|---|---|
| Total Liabilities (in USD) | 2686.686M |
| Revenue TTM (in USD) | 1076.874M |
| Cash (in USD) | 301.654M |
| Market Cap (in USD) | 3,170.395 M |
| Revenue Per Share TTM | 3.828 |
| Gross Profit TTM (in USD) | 557.004M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Sotera Health Co
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
9100 South Hills Boulevard, Broadview Heights, OH, United States, 44147
440 262 1410
Employees: 3000
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Michael B. Petras Jr. | Chairman & CEO | 1969 |
| 2. | Mr. Michael P. Rutz | Pres of Sterigenics | 1971 |
| 3. | Mr. Michael F. Biehl | Interim Chief Financial Officer | 1956 |
| 4. | Mr. Kevin Theriault | Sr. VP of Operations | NA |
| 5. | Mr. Robert G. Hauzie | Chief Information Officer | NA |
| 6. | Joseph Vitale | VP of Investor Relations | NA |
| 7. | Mr. Alexander Dimitrief | Sr. VP & Gen. Counsel | 1959 |
| 8. | Ms. Kristin A. Gibbs | Chief Marketing Officer | NA |
| 9. | Mr. William Lehmann Jr., J.D., M.B.A., MBA | Sr. VP of Strategy & Corp. Devel. | 1966 |
| 10. | Ms. Sally R. Turner | Chief HR Officer | NA |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
-8.130 1.686% | 469.31 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
+1.970 1.119% | 175.86 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
A
Agilent Technologies Inc |
+2.350 1.740% | 134.22 | 34.360 | 26.385 | 6.587 | 7.136 | 6.781 | 23.557 |
|
IDXX
IDEXX Laboratories Inc |
+9.910 1.799% | 549.44 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -243.111M | 175.716M | -38.86M | -0.916M | 24.222M |
| Minority Interest | 0M | -0.239M | 15.897M | 15.067M | 14.757M |
| Net Income | -233.57M | 116.882M | -37.491M | -20.425M | -5.87M |
| Selling General Administrative | 245.714M | 198.158M | 178.525M | 147.48M | 133.363M |
| Gross Profit | 557.004M | 518.672M | 443.572M | 395.431M | 357.252M |
| Reconciled Depreciation | 145.554M | 63.781M | 143.563M | 146.719M | 146.816M |
| Ebit | 248.35M | 256.733M | 206.018M | 183.597M | 169.78M |
| Ebitda | 317.731M | 335.715M | 274.46M | 343.354M | 316.596M |
| Depreciation And Amortization | 69.381M | 78.982M | 68.442M | 159.757M | 146.816M |
| Operating Income | 248.35M | 256.733M | 206.018M | 183.597M | 80.847M |
| Other Operating Expenses | 755.337M | 674.745M | 612.14M | 588.938M | 580.235M |
| Interest Expense | 80.144M | 74.192M | 215.259M | 157.729M | 143.326M |
| Tax Provision | -9.541M | 58.595M | -1.369M | 19.509M | 30.098M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -80.144M | -74.192M | -215.259M | -157.729M | -143.326M |
| Income Tax Expense | -9.541M | 58.595M | -1.369M | 19.509M | 30.098M |
| Total Revenue | 1003.687M | 931.478M | 818.158M | 778.327M | 746.149M |
| Total Operating Expenses | 308.654M | 261.939M | 237.554M | 206.042M | 191.338M |
| Cost Of Revenue | 446.683M | 412.806M | 374.586M | 382.896M | 388.897M |
| Total Other Income Expense Net | -491.461M | -81.017M | -244.878M | -184.513M | 1.634M |
| Net Income From Continuing Ops | -233.57M | 117.121M | -37.491M | -20.425M | -5.876M |
| Net Income Applicable To Common Shares | -233.57M | 116.882M | -38.617M | -20.85M | -5.87M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 3130.42M | 3117.705M | 2789.502M | 2761.279M | 2580.674M |
| Intangible Assets | 416.318M | 491.265M | 598.844M | 643.366M | 696.006M |
| Other Current Assets | 28.086M | 93.089M | 76.566M | 86.733M | 10.439M |
| Total Liab | 2686.686M | 2767.467M | 2203.406M | 2306.705M | 3221.806M |
| Total Stockholder Equity | 443.734M | 350.238M | 586.096M | 454.574M | -642.574M |
| Other Current Liab | 126.621M | 498.893M | 69.175M | 71.586M | 60.736M |
| Common Stock | 2.86M | 2.86M | 2.86M | 2.86M | 2.324M |
| Capital Stock | 2.86M | 2.86M | 2.86M | 2.86M | 2.324M |
| Retained Earnings | -654.44M | -705.816M | -472.246M | -589.128M | -550.511M |
| Good Will | 1111.19M | 1101.768M | 1120.32M | 1115.936M | 1035.865M |
| Other Assets | - | 82.909M | 33.634M | 77.148M | 18.808M |
| Cash | 301.654M | 396.294M | 106.924M | 102.454M | 62.863M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 230.654M | 791.567M | 161.161M | 140.598M | 123.99M |
| Current Deferred Revenue | 13.492M | 12.14M | 8.669M | 6.056M | 3.631M |
| Net Debt | 2025.402M | 1557.216M | 1636.61M | 1722.335M | 2785.512M |
| Short Term Debt | 19.502M | 206.395M | 10.449M | 10.556M | 17.619M |
| Short Long Term Debt | 4.797M | 197.119M | - | - | 16.331M |
| Short Long Term Debt Total | 2327.056M | 1953.51M | 1743.534M | 1824.789M | 2848.375M |
| Other Stockholder Equity | 1187.996M | 1159.847M | 1139.048M | 1134.684M | -0.387M |
| Property Plant Equipment | - | 796.753M | 690.743M | 651.863M | 577.641M |
| Total Current Assets | 557.244M | 645.01M | 345.961M | 315.015M | 252.354M |
| Long Term Investments | - | 0M | 9.405M | 13.457M | - |
| Short Term Investments | 0.715M | - | - | 13.457M | - |
| Net Receivables | 175.519M | 118.482M | 108.183M | 91.735M | 111.582M |
| Long Term Debt | 2223.674M | 1747.115M | 1743.534M | 1824.789M | 2800.873M |
| Inventory | 51.985M | 37.145M | 54.288M | 34.093M | 37.396M |
| Accounts Payable | 71.039M | 74.139M | 72.868M | 52.4M | 42.004M |
| Accumulated Other Comprehensive Income | -92.682M | -106.653M | -83.566M | -93.842M | -94.387M |
| Non Currrent Assets Other | 59.474M | 74.553M | 18.344M | 9.304M | 12.243M |
| Non Current Assets Total | 2573.176M | 2472.695M | 2443.541M | 2446.264M | 2328.32M |
| Capital Lease Obligations | 98.585M | 87.808M | 84.343M | 84.436M | 31.171M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -181.896M | -159.833M | -158.694M | -57.257M | 96.638M |
| Total Cashflows From Investing Activities | -181.896M | -159.833M | -158.694M | -57.257M | 96.638M |
| Total Cash From Financing Activities | 197.761M | -117.286M | 73.432M | -126.03M | -191.857M |
| Net Income | -233.57M | 117.121M | -37.491M | -20.425M | -5.876M |
| Change In Cash | 289.37M | 4.47M | 39.429M | -33.761M | 20.668M |
| Begin Period Cash Flow | 106.924M | 102.454M | 63.025M | 96.786M | 76.118M |
| End Period Cash Flow | 396.294M | 106.924M | 102.454M | 63.025M | 96.786M |
| Total Cash From Operating Activities | 277.961M | 281.545M | 120.585M | 149.041M | 119.563M |
| Depreciation | 145.554M | 150.902M | 143.563M | 146.719M | 146.816M |
| Other Cashflows From Investing Activities | 0.032M | -0.701M | -0.701M | -0.701M | 6.429M |
| Dividends Paid | - | 0M | -150M | -691.17M | 175.845M |
| Change To Inventory | 14.441M | -20.245M | 3.784M | -0.282M | -7.041M |
| Sale Purchase Of Stock | -0.393M | -1.434M | -34M | - | - |
| Other Cashflows From Financing Activities | 198.185M | -15.852M | 278.796M | 3126.224M | -1.378M |
| Capital Expenditures | 182.378M | 102.162M | 53.507M | 57.257M | 72.613M |
| Change In Working Capital | 409.234M | -12.591M | -11.793M | -8.351M | 4.035M |
| Other Non Cash Items | 9.492M | 15.959M | 38.679M | 43.209M | 12.962M |
| Free Cash Flow | 95.583M | 179.383M | 67.078M | 91.784M | 46.95M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Janus Henderson US Opportunistic Alpha | 2 years ago | 7854805 |
| 2. | Janus Henderson Contrarian D | 2 years ago | 7854805 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 4043959 |
| 4. | iShares Core S&P Mid-Cap ETF | 2 years ago | 3859400 |
| 5. | Vanguard Small Cap Index | 2 years ago | 3234941 |
| 6. | Vanguard Explorer Inv | 2 years ago | 2354908 |
| 7. | Janus Henderson Triton D | 2 years ago | 2347169 |
| 8. | Janus Henderson US SMID Cap Growth | 2 years ago | 2347169 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 1862955 |
| 10. | Vanguard Small Cap Growth Index Inv | 2 years ago | 1829202 |
| 11. | T. Rowe Price US Small-Cap Core Equity | 2 years ago | 1760880 |
| 12. | T. Rowe Price Small-Cap Stock | 2 years ago | 1760880 |
| 13. | Janus Henderson Global Life Sciences D | 2 years ago | 1507569 |
| 14. | Janus Henderson Global Life Sciences | 2 years ago | 1507569 |
| 15. | Janus Selection Global Life Science AUSD | 2 years ago | 1150375 |
| 16. | Janus Henderson Glb Life Scn I2 USD | 2 years ago | 1150375 |
| 17. | SPDR® S&P MIDCAP 400 ETF Trust | 2 years ago | 1012461 |
| 18. | T. Rowe Price U.S. SC Core Eq Tr-Z | 2 years ago | 954546 |
| 19. | Meridian Growth Legacy | 2 years ago | 877358 |
| 20. | iShares S&P Mid-Cap 400 Growth ETF | 2 years ago | 848276 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Warburg Pincus LLC | 2 years ago | 88822952 |
| 2. | GTCR LLC | 2 years ago | 59215301 |
| 3. | HHG PLC | 2 years ago | 14892868 |
| 4. | Vanguard Group Inc | 2 years ago | 12145110 |
| 5. | BlackRock Inc | 2 years ago | 9448915 |
| 6. | Sachem Head Capital Management LP | 2 years ago | 7910000 |
| 7. | T. Rowe Price Investment Management,Inc. | 2 years ago | 5036865 |
| 8. | MIG Capital, LLC | 2 years ago | 5035451 |
| 9. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 2 years ago | 4735537 |
| 10. | Sessa Capital IM LP | 2 years ago | 4000000 |
| 11. | Maverick Capital Ltd | 2 years ago | 3567120 |
| 12. | P2 Capital Partners, LLC | 2 years ago | 2950000 |
| 13. | Millennium Management LLC | 2 years ago | 2936512 |
| 14. | State Street Corporation | 2 years ago | 2751236 |
| 15. | Irenic Capital Management LP | 2 years ago | 2602959 |
| 16. | Lakewood Capital Management, LP | 2 years ago | 2307739 |
| 17. | Dimensional Fund Advisors, Inc. | 2 years ago | 2303017 |
| 18. | Hawk Ridge Management LLC | 2 years ago | 1878858 |
| 19. | Geode Capital Management, LLC | 2 years ago | 1800470 |
| 20. | Charles Schwab Investment Management Inc | 2 years ago | 1143846 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...